Log in to search using one of your social media accounts:

 

FDA allows marketing of test to aid in the detection of certain leukemias and lymphomas

The U.S. Food and Drug Administration today allowed marketing of ClearLLab Reagents (T1, T2, B1, B2, M), the first agency authorized test for use with flow cytometry to aid in the detection of several leukemias and lymphomas, including chronic leukemia, acute leukemia, non-Hodgkin lymphoma, myeloma, myelodysplastic syndrome (MDS) and myeloproliferative neoplasms (MPN).
Source: Food and Drug Administration - Category: American Health Source Type: news

Related Links:

Abstract Leukemoid reaction (LR) is a reactive disease that exhibits abnormal blood values similar to leukemia, but not due to leukemia. One report showed that neonatal LR (NLR) was associated with elevated serum granulocyte colony stimulating factor (G-CSF) in only 30% of the study neonates. NLR is not always associated with the elevation of serum G-CSF. NLR was defined as a white blood cell count of ≥ 40 × 103/μL and/or blast cell concentration of> 2%. We have focused on NLR with fetal inflammatory response syndrome (FIRS), defined as a fetal systemic inflammatory reaction triggered by intrauterin...
Source: The Tohoku Journal of Experimental Medicine - Category: Research Authors: Tags: Tohoku J Exp Med Source Type: research
Peripheral nervous system damage from hematologic malignancies is related to neoplastic cells infiltration of peripheral nerves or to monoclonal antibody production cross-reacting with peripheral nerves' antigens. Neurolymphomatosis (NL), a rare manifestation of hematologic malignancies, occurs when malignant cells invade the peripheral nerves leading to various manifestations. Here, we report a case of NL with 2 hematologic malignancies in a 79-year-old woman presenting with lower extremity pain/weakness. Investigation revealed anemia, IgM kappa monoclonal gammopathy, and elevated anti-MAG titer. Electrodiagnostic studies...
Source: Journal of Clinical Neuromuscular Disease - Category: Neurology Tags: Case Review Source Type: research
Introduction: Bacterial infections are frequent complications occurring after autologous hematopoietic stem-cell transplantation (AHSCT). Herein, we identified the bacterial ecology and its antibiogram in AHSCT patients. We assessed the incidence, contributing factors and outcome of prolonged neutropenia and bacteremia post-AHSCT in the absence of antibacterial prophylaxis.Methodology: This is a retrospective chart review of 190 adult patients who underwent AHSCT for lymphoma and multiple myeloma, between 2005 and 2015 at a Lebanese hospital.Results: Most of the isolated bacteria originated from urine (49%) followed by blo...
Source: The Journal of Infection in Developing Countries - Category: Infectious Diseases Source Type: research
Conclusion: The study did not reach its primary endpoint of a 1-year PFS of 67.3%. Reasons for this could include low accrual, high-risk disease, and inadequate debulking provided by 2 cycles of ESHAP. However, this protocol was associated with tolerable toxicity, high ORR, and high OS. Further studies would optimize debulking and focus on high-risk FL patients.Oncology
Source: Oncology - Category: Cancer & Oncology Source Type: research
Single-agent MOR208 showed promising activity with long-lasting responses in aggressive and indolent NHL subtypes, including in rituximab-refractory disease.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Tags: Diffuse Large B-Cell Lymphoma Follicular Lymphoma Source Type: news
Summary A few decades ago, the chances of survival for patients with a haematological malignancy needing Intensive Care Unit (ICU) support were minimal. As a consequence, ICU admission policy was cautious. We hypothesized that the long‐term outcome of patients with a haematological malignancy admitted to the ICU has improved in recent years. Furthermore, our objective was to evaluate the predictive value of the Acute Physiology and Chronic Health Evaluation (APACHE) II score. A total of 1095 patients from 5 Dutch university hospitals were included from 2003 until 2015. We studied the prevalence of patients' characteristi...
Source: British Journal of Haematology - Category: Hematology Authors: Tags: Research Paper Source Type: research
Source: British Journal of Haematology - Category: Hematology Authors: Tags: Images in Haematology Source Type: research
Source: British Journal of Haematology - Category: Hematology Authors: Tags: Correspondence Source Type: research
Summary Brentuximab vedotin (BV) is an anti‐CD30 antibody‐drug conjugate. Preliminary data suggest that BV might improve outcomes after allogeneic stem cell transplantation (SCT) for Hodgkin lymphoma (HL) when used as pre‐transplant salvage therapy. Between 2010 and 2014, 428 adult patients underwent an allogeneic SCT for classical HL at participating centres of the European Society for Blood and Marrow Transplantation. We compared the outcomes of 210 patients who received BV prior to allogeneic SCT with that of 218 patients who did not receive BV. The median follow‐up for survivors was 41 months. Patients in ...
Source: British Journal of Haematology - Category: Hematology Authors: Tags: Research Paper Source Type: research
The HDAC inhibitor SAHA regulates CBX2 stability via a SUMO-triggered ubiquitin-mediated pathway in leukemia, Published online: 22 February 2018; doi:10.1038/s41388-018-0143-1The HDAC inhibitor SAHA regulates CBX2 stability via a SUMO-triggered ubiquitin-mediated pathway in leukemia
Source: Oncogene - Category: Cancer & Oncology Authors: Source Type: research
More News: Acute Leukemia | American Health | Chronic Leukemia | Food and Drug Administration (FDA) | Leukemia | Lymphoma | Marketing | Myelodysplastic Syndrome | Myeloma | Myeloproliferative Disorders | Non-Hodgkin's Lymphoma